BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Queensland Health
US Department of Justice
Federal Trade Commission
Farmers Insurance
Johnson and Johnson

Generated: December 15, 2017

DrugPatentWatch Database Preview

Details for Patent: 4,536,518

« Back to Dashboard

Summary for Patent: 4,536,518

Title: Antidepressant derivatives of cis-4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine
Abstract:Novel cis-isomeric derivatives of 4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine are useful as antidepressant agents. These novel compounds act to block the synaptosomal uptake of serotonin (5-hydroxy-tryptamine), thereby alleviating serotonin abnormalities at central receptor sites. The preferred embodiment is the enantiomer cis-(1S)-N-methyl-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenam ine and its pharmaceutically acceptable acid addition salts.
Inventor(s): Welch, Jr.; Willard M. (Mystic, CT), Harbert; Charles A. (Waterford, CT), Koe; B. Kenneth (Gales Ferry, CT), Kraska; Allen R. (East Lyme, CT)
Assignee: Pfizer Inc. (New York, NY)
Application Number:06/090,240
Patent Claim Types:
see list of patent claims
Compound; Use; Composition;

No matches for this query

International Patent Family for Patent: 4,536,518

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria2668► Subscribe
Australia517357► Subscribe
Australia6389780► Subscribe
Bosnia and Herzegovina97149► Subscribe
Bosnia and Herzegovina97150► Subscribe
Bulgaria60333► Subscribe
Canada1130815► Subscribe
Czechoslovakia238609► Subscribe
Czechoslovakia238617► Subscribe
Czechoslovakia238618► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

US Department of Justice
Boehringer Ingelheim
Queensland Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch: